论文部分内容阅读
目的比较吡柔比星与丝裂霉素膀胱灌注预防浅表性膀胱尿路上皮癌TUR-Bt术后的效疗与安全性。方法将47例浅表性膀胱尿路上皮癌TUR-Bt术后的患者,随机分成2组,分别用吡柔比星和丝裂霉素作膀胱灌注,定期复查膀胱镜及血常规、尿常规、肝肾功能检查,观察其治疗效果及副作用。结果吡柔比星组2例(8.7%)复发,丝裂霉素组4例(16.7%)复发,复发率吡柔比星组明显低于丝裂霉素组(P<0.05);膀胱刺激症,吡柔比星组2例(8.7%),丝裂霉素组3例(12.5%);其他副作用方面吡柔比星出现排尿困难1例。结论丝裂霉素及吡柔比星膀胱灌注安全性相似,与丝裂霉素相比,吡柔比星具有膀胱内化疗药保留时间短、疗效高等优点。
Objective To compare the efficacy and safety of intravesical instillation of pirarubicin and mitomycin C in preventing TUR-Bt superficial bladder cancer. Methods 47 cases of superficial bladder urothelial carcinoma TUR-Bt postoperative patients were randomly divided into two groups, respectively, with pirarubicin and mitomycin for bladder perfusion, regular review of cystoscopy and blood, urine routine , Liver and kidney function tests to observe the treatment effect and side effects. Results Recurrence occurred in 2 patients (8.7%) in the pirarubicin group and in 4 patients (16.7%) in the mitomycin group. The relapse rate in the pirarubicin group was significantly lower than that in the mitomycin group (P <0.05) Two patients (8.7%) were treated with pirarubicin and three patients (12.5%) were treated with mitomycin. One case was dyspnea due to other side effects. Conclusion Mitomycin and pirarubicin are similar in bladder perfusion safety. Compared with mitomycin, pirarubicin has the advantages of short retention time and high curative effect in intravesical chemotherapy.